Holen Sie sich die Stockscreener-App
27.50
2.90%
-0.82
Handel nachbörslich:
27.54
0.04
+0.15%
Schlusskurs vom Vortag:
$28.32
Offen:
$28.05
24-Stunden-Volumen:
106.81K
Relative Volume:
0.60
Marktkapitalisierung:
$393.18M
Einnahmen:
$138.20M
Nettoeinkommen (Verlust:
$5.52M
KGV:
72.37
EPS:
0.38
Netto-Cashflow:
$9.86M
1W Leistung:
+0.51%
1M Leistung:
-5.56%
6M Leistung:
-0.51%
1J Leistung:
-26.80%
1-Tages-Spanne:
$27.40
$28.12
1-Wochen-Bereich:
$26.73
$28.67
52-Wochen-Spanne:
$26.00
$40.38
Surmodics Inc Stock (SRDX) Company Profile
Firmenname
Surmodics Inc
Sektor
Branche
Telefon
(952) 500-7000
Adresse
9924 W 74TH ST, EDEN PRAIRIE, MN
Vergleichen Sie SRDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
27.50 | 404.91M | 138.20M | 5.52M | 9.86M | 0.38 |
|
ABT
Abbott Laboratories
|
125.80 | 215.34B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.84 | 146.15B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
362.61 | 136.97B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.42 | 115.69B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
84.15 | 48.77B | 5.88B | 1.34B | 577.90M | 2.3455 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Hochstufung | Lake Street | Hold → Buy |
| 2023-06-13 | Hochstufung | Needham | Hold → Buy |
| 2023-02-13 | Herabstufung | Needham | Buy → Hold |
| 2020-07-23 | Hochstufung | Needham | Hold → Buy |
| 2019-12-11 | Herabstufung | Needham | Buy → Hold |
| 2019-11-01 | Herabstufung | Lake Street | Buy → Hold |
| 2019-08-01 | Bestätigt | Needham | Buy |
| 2019-05-02 | Bestätigt | Lake Street | Buy |
| 2019-05-02 | Bestätigt | Needham | Buy |
| 2019-02-21 | Bestätigt | Needham | Buy |
| 2018-05-16 | Bestätigt | Needham | Buy |
| 2018-03-01 | Hochstufung | Sidoti | Neutral → Buy |
| 2018-02-28 | Bestätigt | Lake Street | Buy |
| 2018-02-28 | Eingeleitet | Needham | Buy |
| 2017-07-14 | Eingeleitet | Lake Street | Buy |
| 2016-11-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-10-06 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-05-03 | Bestätigt | Barrington Research | Outperform |
| 2015-08-06 | Bestätigt | Barrington Research | Outperform |
| 2015-03-27 | Eingeleitet | Dougherty & Company | Buy |
| 2014-02-25 | Eingeleitet | Laidlaw | Buy |
| 2013-08-01 | Hochstufung | Feltl & Co. | Buy → Strong Buy |
| 2012-11-12 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Surmodics Inc Aktie (SRDX) Neueste Nachrichten
Surmodics reports high success rate for Pounce thrombectomy device By Investing.com - Investing.com Canada
Will earnings trigger a reversal in Surmodics Inc.2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Surmodics (SRDX) Releases Positive Results from PROWL Registry S - GuruFocus
Surmodics reports high success rate for Pounce thrombectomy device - Investing.com
Surmodics shares data from 160 patients in PROWL registry using Pounce for real-world limb ischemia - MarketScreener
Published on: 2025-11-04 05:20:51 - newser.com
Surmodics (NASDAQ: SRDX) PROWL Registry Shows 0.6% Device-Related MAEs, 94.8% Flow Restoration - Stock Titan
Key metrics from Surmodics Inc.’s quarterly dataPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Should you wait for a breakout in Surmodics Inc.2025 Bull vs Bear & Safe Capital Growth Tips - newser.com
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3 - BioSpace
Discipline and Rules-Based Execution in SRDX Response - news.stocktradersdaily.com
Surmodics to present updated data on Pounce thrombectomy system By Investing.com - Investing.com Nigeria
Surmodics spotlights unique arterial thrombotic study at VIVA25 - Traders Union
What earnings revisions data tells us about Surmodics Inc.Weekly Risk Summary & Community Verified Trade Signals - newser.com
Can Surmodics Inc. stock deliver sustainable ROE2025 Stock Rankings & Daily Momentum Trading Reports - newser.com
Is it time to cut losses on Surmodics Inc.Portfolio Update Report & Fast Momentum Stock Entry Tips - newser.com
Surmodics to present updated data on Pounce thrombectomy system - Investing.com
Y Intercept Hong Kong Ltd Buys Shares of 42,975 Surmodics, Inc. $SRDX - MarketBeat
Can Surmodics Inc. stock reach $100 price targetJuly 2025 News Drivers & Stock Market Timing Techniques - newser.com
Is Surmodics Inc. stock resilient to inflationWeekly Market Outlook & Accurate Entry/Exit Alerts - newser.com
Will Surmodics Inc. stock return to pre crisis levelsWeekly Stock Recap & AI Powered Trade Plan Recommendations - newser.com
How to interpret RSI for Surmodics Inc. stockJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Is Surmodics Inc. stock a safe investment in uncertain markets2025 Stock Rankings & Free Real-Time Volume Trigger Notifications - newser.com
How institutional ownership impacts Surmodics Inc. stock2025 Valuation Update & Risk Controlled Stock Pick Alerts - newser.com
Published on: 2025-11-01 01:11:15 - newser.com
Is Surmodics Inc. stock entering bullish territoryJuly 2025 Short Interest & Growth Focused Entry Reports - newser.com
Published on: 2025-10-31 04:30:06 - newser.com
Published on: 2025-10-31 04:03:38 - newser.com
Regression analysis insights on Surmodics Inc. performanceJuly 2025 Summary & Reliable Volume Spike Alerts - newser.com
Surmodics (SRDX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform - BioSpace
Surmodics (SRDX) PROWL Study Highlights Success in Thrombectomy Procedures - GuruFocus
Surmodics, Inc. (NASDAQ:SRDX) Given Average Rating of "Hold" by Analysts - MarketBeat
Finanzdaten der Surmodics Inc-Aktie (SRDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):